Snowball logo
logo
ABL_logo

Abbott Laboratories

€93.46+€1.58  (1.72%)
Estimate
P/E
40.8
EPS
2.29
Beta
0.583
Growth
Revenue, YoY
37.26%
Net income, YoY
-32.89%
Dividends
Dividend yield
2.15%
Annual payout
$2.25
Next ex. div date
October 15, 26
Payout
63.09%
Div.growth, 5y
10.38%
Dividend growth streak
6 y
Div.rating
About the company
Ticker
ABL
ISIN
US0028241000
Country
United States of America
Sector (GICS)
Healthcare
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Frequently asked questions

What sector does Abbott Laboratories (ABL) operate in?

Abbott Laboratories belongs to the Healthcare sector and operates in the Medical Devices industry.

What is Abbott Laboratories (ABL) current stock price?

As of the latest data, Abbott Laboratories stock price is €93.46, with a previous close of €91.88. Abbott Laboratories gained €1.58 in the last trading session, representing a 1.72% increase.

What is Abbott Laboratories (ABL) current market capitalization?

Abbott Laboratories market cap is approximately 161.72 billion.

What is Abbott Laboratories (ABL) Earnings Per Share (EPS)?

The trailing EPS is €2.29.

What is Abbott Laboratories (ABL) Price-to-Earnings (P/E) ratio?

Abbott Laboratories current P/E ratio is 40.81.

What is Abbott Laboratories (ABL) EBITDA?

Abbott Laboratories EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 1.51 billion.

Does Abbott Laboratories (ABL) pay dividends?

Yes. Abbott Laboratories pays quarterly dividends with an annualized yield of 2.15% and an estimated annual payout of €2.25 per share.

When is the next ex-dividend date for Abbott Laboratories (ABL)?

The next ex-dividend date is scheduled for October 15, 2026.

When is Abbott Laboratories (ABL) next earnings report?

Abbott Laboratories is expected to release its next earnings report on September 30, 2026.

What is Abbott Laboratories (ABL) beta (volatility) score?

Abbott Laboratories has a beta of 0.583, indicating lower volatility than the overall market.